CARMEL, Ind., Nov. 7, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare company addressing some of healthcare's most significant challenges in behavioral and mental health, digital health, and population health today announced the receipt of a two-year contract to assess the needs of the Hispanic and Latino communities in Hennepin County, Minnesota and to implement Culturally and Linguistically Appropriate Services (CLAS) standards in support of those needs.
Developed by the U.S. Department of Health and Human Services' (HHS) Office of Minority Health, the National CLAS standards are a set of 15 action steps for implementing culturally and linguistically appropriate services. According to HHS, "CLAS standards are intended to advance health equity, improve quality, and help eliminate healthcare disparities."
Syra Health is partnering with a Federally Qualified Health Center – People's Center Clinics and Services in Hennepin County to perform mixed methods research, identify baseline measurements, and to help the clinic implement CLAS standards.
"We are enthusiastic about the opportunity this CLAS contract presents," said Dr. Srikant Devaraj, Vice President of Data Analytics, Syra Health. "We are confident that our strategic approach, advanced tools, and experienced team of health equity experts will lead to a successful assessment and implementation of CLAS standards for the benefit of improved health outcomes of Hispanic and Latino communities."
The community needs and CLAS standards assessment will help the State of Minnesota Department of Human Services, Office of Medicaid Medical Director identify gaps in healthcare delivery, and further promote health equity. Metrics will be established as part of the contract with ongoing monitoring. Syra Health will also provide necessary CLAS trainings.
ABOUT SYRA HEALTH CORP.
Syra Health is a healthcare company addressing some of healthcare's most significant challenges. Syra Health specializes in behavioral and mental health, digital health, and population health. Syra Health's solutions are centered on prevention, improved access, and affordable care. For more information, please visit www.syrahealth.com.
SAFE HARBOR STATEMENT
Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors discussed in the "Risk Factors" section of the prospectus filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health Corp.
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.13 |
Daily Change: | -0.08 -37.99 |
Daily Volume: | 1,535,458 |
Market Cap: | US$1.140M |
February 18, 2025 December 02, 2024 November 26, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load